POS-02.74: Detrusor overactivity after prostate resection: preventing postoperative incontinence with darifenacin

Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

“…Therefore, OAB symptom occurrence and detrusor overactivity found in these studies may not be fully explained by detrusor overactivity caused by BOO such as structural changes in the detrusor (for example, detrusor denervation due to functional overload) [43,44]. There are indications that OAB and incontinence after transurethral resection of the prostate are frequently a result of detrusor overactivity that persists independently from the elimination of obstruction by prostatectomy [45]. With respect to cited findings, it cannot be excluded that concomitant LUTS (or at least the "irritative symptoms" of LUTS) and BPH may occur without causal connection with BPE and could possibly be due to detrusor overactivity, which may be present as a functional bladder pathology distinct from BPE or BOO.…”

Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

“…Several studies have meanwhile shown that antimuscarinic drugs, alone or in combination with α -blockers, are also effective on LUTS in association with BPH [ 39 , 40 , 41• , 42• , 43 ]. There are indications that OAB and incontinence after transurethral resection of the prostate are frequently a result of detrusor overactivity that persists independently from the elimination of obstruction by prostatectomy [ 45 ]. So far, based on limited experience, there are no clear signs that antimuscarinic agents cause a signifi cant rise in residual urine volume due to BOO or urinary retention.…”